Search

Your search keyword '"Poulikakos, Poulikos I."' showing total 249 results
Start Over Author "Poulikakos, Poulikos I."
249 results on '"Poulikakos, Poulikos I."'

1. Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st–3rd, 2022—Naples, Italy)

Author

Ascierto, Paolo A., Agarwala, Sanjiv S., Warner, Allison Betof, Ernstoff, Marc S., Fox, Bernard A., Gajewski, Thomas F., Galon, Jérôme, Garbe, Claus, Gastman, Brian R., Gershenwald, Jeffrey E., Kalinski, Pawel, Krogsgaard, Michelle, Leidner, Rom S., Lo, Roger S., Menzies, Alexander M., Michielin, Olivier, Poulikakos, Poulikos I., Weber, Jeffrey S., Caracò, Corrado, Osman, Iman, Puzanov, Igor, and Thurin, Magdalena

Published
2023
Full Text
View/download PDF

4. Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd – 4th, 2021, Italy)

Author

Ascierto, Paolo A., Agarwala, Sanjiv S., Blank, Christian, Caracò, Corrado, Carvajal, Richard D., Ernstoff, Marc S., Ferrone, Soldano, Fox, Bernard A., Gajewski, Thomas F., Garbe, Claus, Grob, Jean-Jacques, Hamid, Omid, Krogsgaard, Michelle, Lo, Roger S., Lund, Amanda W., Madonna, Gabriele, Michielin, Olivier, Neyns, Bart, Osman, Iman, Peters, Solange, Poulikakos, Poulikos I., Quezada, Sergio A., Reinfeld, Bradley, Zitvogel, Laurence, Puzanov, Igor, and Thurin, Magdalena

Published
2022
Full Text
View/download PDF

7. BRAFV600E-induced senescence drives Langerhans cell histiocytosis pathophysiology

Author

Bigenwald, Camille, Le Berichel, Jessica, Wilk, C. Matthias, Chakraborty, Rikhia, Chen, Steven T., Tabachnikova, Alexandra, Mancusi, Rebecca, Abhyankar, Harshal, Casanova-Acebes, Maria, Laface, Ilaria, Akturk, Guray, Jobson, Jenielle, Karoulia, Zoi, Martin, Jerome C., Grout, John, Rafiei, Anahita, Lin, Howard, Manz, Markus G., Baccarini, Alessia, Poulikakos, Poulikos I., Brown, Brian D., Gnjatic, Sacha, Lujambio, Amaia, McClain, Kenneth L., Picarsic, Jennifer, Allen, Carl E., and Merad, Miriam

Published
2021
Full Text
View/download PDF

11. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

Author

Poulikakos, Poulikos I, Persaud, Yogindra, Janakiraman, Manickam, Kong, Xiangju, Ng, Charles, Moriceau, Gatien, Shi, Hubing, Atefi, Mohammad, Titz, Bjoern, Gabay, May Tal, Salton, Maayan, Dahlman, Kimberly B, Tadi, Madhavi, Wargo, Jennifer A, Flaherty, Keith T, Kelley, Mark C, Misteli, Tom, Chapman, Paul B, Sosman, Jeffrey A, Graeber, Thomas G, Ribas, Antoni, Lo, Roger S, Rosen, Neal, and Solit, David B

Subjects
Genetics, Cancer, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Alternative Splicing, Animals, Cell Line, Tumor, Drug Resistance, Neoplasm, Exons, Extracellular Signal-Regulated MAP Kinases, Humans, Indoles, MAP Kinase Signaling System, Melanoma, Mice, Mutant Proteins, Protein Isoforms, Protein Kinase Inhibitors, Protein Multimerization, Proto-Oncogene Proteins B-raf, Sulfonamides, Vemurafenib, General Science & Technology
Abstract

Activated RAS promotes dimerization of members of the RAF kinase family. ATP-competitive RAF inhibitors activate ERK signalling by transactivating RAF dimers. In melanomas with mutant BRAF(V600E), levels of RAS activation are low and these drugs bind to BRAF(V600E) monomers and inhibit their activity. This tumour-specific inhibition of ERK signalling results in a broad therapeutic index and RAF inhibitors have remarkable clinical activity in patients with melanomas that harbour mutant BRAF(V600E). However, resistance invariably develops. Here, we identify a new resistance mechanism. We find that a subset of cells resistant to vemurafenib (PLX4032, RG7204) express a 61-kDa variant form of BRAF(V600E), p61BRAF(V600E), which lacks exons 4-8, a region that encompasses the RAS-binding domain. p61BRAF(V600E) shows enhanced dimerization in cells with low levels of RAS activation, as compared to full-length BRAF(V600E). In cells in which p61BRAF(V600E) is expressed endogenously or ectopically, ERK signalling is resistant to the RAF inhibitor. Moreover, a mutation that abolishes the dimerization of p61BRAF(V600E) restores its sensitivity to vemurafenib. Finally, we identified BRAF(V600E) splicing variants lacking the RAS-binding domain in the tumours of six of nineteen patients with acquired resistance to vemurafenib. These data support the model that inhibition of ERK signalling by RAF inhibitors is dependent on levels of RAS-GTP too low to support RAF dimerization and identify a novel mechanism of acquired resistance in patients: expression of splicing isoforms of BRAF(V600E) that dimerize in a RAS-independent manner.

Published
2011

12. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

Author

Poulikakos, Poulikos I, Zhang, Chao, Bollag, Gideon, Shokat, Kevan M, and Rosen, Neal

Subjects
Biochemistry and Cell Biology, Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Biological Sciences, Cancer, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Adenosine Triphosphate, Animals, Catalytic Domain, Cell Line, Cell Line, Tumor, Enzyme Activation, Extracellular Signal-Regulated MAP Kinases, Humans, Indoles, MAP Kinase Signaling System, Mice, Mitogen-Activated Protein Kinase Kinases, Models, Biological, Neoplasms, Phosphorylation, Protein Binding, Protein Kinase Inhibitors, Protein Multimerization, Proto-Oncogene Proteins B-raf, Sulfonamides, Transcriptional Activation, raf Kinases, ras Proteins, General Science & Technology
Abstract

Tumours with mutant BRAF are dependent on the RAF-MEK-ERK signalling pathway for their growth. We found that ATP-competitive RAF inhibitors inhibit ERK signalling in cells with mutant BRAF, but unexpectedly enhance signalling in cells with wild-type BRAF. Here we demonstrate the mechanistic basis for these findings. We used chemical genetic methods to show that drug-mediated transactivation of RAF dimers is responsible for paradoxical activation of the enzyme by inhibitors. Induction of ERK signalling requires direct binding of the drug to the ATP-binding site of one kinase of the dimer and is dependent on RAS activity. Drug binding to one member of RAF homodimers (CRAF-CRAF) or heterodimers (CRAF-BRAF) inhibits one protomer, but results in transactivation of the drug-free protomer. In BRAF(V600E) tumours, RAS is not activated, thus transactivation is minimal and ERK signalling is inhibited in cells exposed to RAF inhibitors. These results indicate that RAF inhibitors will be effective in tumours in which BRAF is mutated. Furthermore, because RAF inhibitors do not inhibit ERK signalling in other cells, the model predicts that they would have a higher therapeutic index and greater antitumour activity than mitogen-activated protein kinase (MEK) inhibitors, but could also cause toxicity due to MEK/ERK activation. These predictions have been borne out in a recent clinical trial of the RAF inhibitor PLX4032 (refs 4, 5). The model indicates that promotion of RAF dimerization by elevation of wild-type RAF expression or RAS activity could lead to drug resistance in mutant BRAF tumours. In agreement with this prediction, RAF inhibitors do not inhibit ERK signalling in cells that coexpress BRAF(V600E) and mutant RAS.

Published
2010

15. Supplementary Video 7 from Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling

Author

Adamopoulos, Christos, primary, Ahmed, Tamer A., primary, Tucker, Maxwell R., primary, Ung, Peter M.U., primary, Xiao, Min, primary, Karoulia, Zoi, primary, Amabile, Angelo, primary, Wu, Xuewei, primary, Aaronson, Stuart A., primary, Ang, Celina, primary, Rebecca, Vito W., primary, Brown, Brian D., primary, Schlessinger, Avner, primary, Herlyn, Meenhard, primary, Wang, Qi, primary, Shaw, David E., primary, and Poulikakos, Poulikos I., primary

Published
2023
Full Text
View/download PDF

17. Supplementary Figures from Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling

Author

Adamopoulos, Christos, primary, Ahmed, Tamer A., primary, Tucker, Maxwell R., primary, Ung, Peter M.U., primary, Xiao, Min, primary, Karoulia, Zoi, primary, Amabile, Angelo, primary, Wu, Xuewei, primary, Aaronson, Stuart A., primary, Ang, Celina, primary, Rebecca, Vito W., primary, Brown, Brian D., primary, Schlessinger, Avner, primary, Herlyn, Meenhard, primary, Wang, Qi, primary, Shaw, David E., primary, and Poulikakos, Poulikos I., primary

Published
2023
Full Text
View/download PDF

18. Supplementary Video 2 from Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling

Author

Adamopoulos, Christos, primary, Ahmed, Tamer A., primary, Tucker, Maxwell R., primary, Ung, Peter M.U., primary, Xiao, Min, primary, Karoulia, Zoi, primary, Amabile, Angelo, primary, Wu, Xuewei, primary, Aaronson, Stuart A., primary, Ang, Celina, primary, Rebecca, Vito W., primary, Brown, Brian D., primary, Schlessinger, Avner, primary, Herlyn, Meenhard, primary, Wang, Qi, primary, Shaw, David E., primary, and Poulikakos, Poulikos I., primary

Published
2023
Full Text
View/download PDF

19. Supplementary Video 6 from Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling

Author

Adamopoulos, Christos, primary, Ahmed, Tamer A., primary, Tucker, Maxwell R., primary, Ung, Peter M.U., primary, Xiao, Min, primary, Karoulia, Zoi, primary, Amabile, Angelo, primary, Wu, Xuewei, primary, Aaronson, Stuart A., primary, Ang, Celina, primary, Rebecca, Vito W., primary, Brown, Brian D., primary, Schlessinger, Avner, primary, Herlyn, Meenhard, primary, Wang, Qi, primary, Shaw, David E., primary, and Poulikakos, Poulikos I., primary

Published
2023
Full Text
View/download PDF

20. Supplementary Video 5 from Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling

Author

Adamopoulos, Christos, primary, Ahmed, Tamer A., primary, Tucker, Maxwell R., primary, Ung, Peter M.U., primary, Xiao, Min, primary, Karoulia, Zoi, primary, Amabile, Angelo, primary, Wu, Xuewei, primary, Aaronson, Stuart A., primary, Ang, Celina, primary, Rebecca, Vito W., primary, Brown, Brian D., primary, Schlessinger, Avner, primary, Herlyn, Meenhard, primary, Wang, Qi, primary, Shaw, David E., primary, and Poulikakos, Poulikos I., primary

Published
2023
Full Text
View/download PDF

21. Supplementary Table from AKT Degradation Selectively Inhibits the Growth of PI3K/PTEN Pathway–Mutant Cancers with Wild-Type KRAS and BRAF by Destabilizing Aurora Kinase B

Author

Xu, Jia, primary, Yu, Xufen, primary, Martin, Tiphaine C., primary, Bansal, Ankita, primary, Cheung, Kakit, primary, Lubin, Abigail, primary, Stratikopoulos, Elias, primary, Cahuzac, Kaitlyn M., primary, Wang, Li, primary, Xie, Ling, primary, Zhou, Royce, primary, Shen, Yudao, primary, Wu, Xuewei, primary, Yao, Shen, primary, Qiao, Ruifang, primary, Poulikakos, Poulikos I., primary, Chen, Xian, primary, Liu, Jing, primary, Jin, Jian, primary, and Parsons, Ramon, primary

Published
2023
Full Text
View/download PDF

22. Supplementary Video 4 from Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling

Author

Adamopoulos, Christos, primary, Ahmed, Tamer A., primary, Tucker, Maxwell R., primary, Ung, Peter M.U., primary, Xiao, Min, primary, Karoulia, Zoi, primary, Amabile, Angelo, primary, Wu, Xuewei, primary, Aaronson, Stuart A., primary, Ang, Celina, primary, Rebecca, Vito W., primary, Brown, Brian D., primary, Schlessinger, Avner, primary, Herlyn, Meenhard, primary, Wang, Qi, primary, Shaw, David E., primary, and Poulikakos, Poulikos I., primary

Published
2023
Full Text
View/download PDF

23. Data from AKT Degradation Selectively Inhibits the Growth of PI3K/PTEN Pathway–Mutant Cancers with Wild-Type KRAS and BRAF by Destabilizing Aurora Kinase B

Author

Xu, Jia, primary, Yu, Xufen, primary, Martin, Tiphaine C., primary, Bansal, Ankita, primary, Cheung, Kakit, primary, Lubin, Abigail, primary, Stratikopoulos, Elias, primary, Cahuzac, Kaitlyn M., primary, Wang, Li, primary, Xie, Ling, primary, Zhou, Royce, primary, Shen, Yudao, primary, Wu, Xuewei, primary, Yao, Shen, primary, Qiao, Ruifang, primary, Poulikakos, Poulikos I., primary, Chen, Xian, primary, Liu, Jing, primary, Jin, Jian, primary, and Parsons, Ramon, primary

Published
2023
Full Text
View/download PDF

24. Data from Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling

Author

Adamopoulos, Christos, primary, Ahmed, Tamer A., primary, Tucker, Maxwell R., primary, Ung, Peter M.U., primary, Xiao, Min, primary, Karoulia, Zoi, primary, Amabile, Angelo, primary, Wu, Xuewei, primary, Aaronson, Stuart A., primary, Ang, Celina, primary, Rebecca, Vito W., primary, Brown, Brian D., primary, Schlessinger, Avner, primary, Herlyn, Meenhard, primary, Wang, Qi, primary, Shaw, David E., primary, and Poulikakos, Poulikos I., primary

Published
2023
Full Text
View/download PDF

25. Supplementary Tables from Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling

Author

Adamopoulos, Christos, primary, Ahmed, Tamer A., primary, Tucker, Maxwell R., primary, Ung, Peter M.U., primary, Xiao, Min, primary, Karoulia, Zoi, primary, Amabile, Angelo, primary, Wu, Xuewei, primary, Aaronson, Stuart A., primary, Ang, Celina, primary, Rebecca, Vito W., primary, Brown, Brian D., primary, Schlessinger, Avner, primary, Herlyn, Meenhard, primary, Wang, Qi, primary, Shaw, David E., primary, and Poulikakos, Poulikos I., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Figure from AKT Degradation Selectively Inhibits the Growth of PI3K/PTEN Pathway–Mutant Cancers with Wild-Type KRAS and BRAF by Destabilizing Aurora Kinase B

Author

Xu, Jia, primary, Yu, Xufen, primary, Martin, Tiphaine C., primary, Bansal, Ankita, primary, Cheung, Kakit, primary, Lubin, Abigail, primary, Stratikopoulos, Elias, primary, Cahuzac, Kaitlyn M., primary, Wang, Li, primary, Xie, Ling, primary, Zhou, Royce, primary, Shen, Yudao, primary, Wu, Xuewei, primary, Yao, Shen, primary, Qiao, Ruifang, primary, Poulikakos, Poulikos I., primary, Chen, Xian, primary, Liu, Jing, primary, Jin, Jian, primary, and Parsons, Ramon, primary

Published
2023
Full Text
View/download PDF

27. Supplementary Data from AKT Degradation Selectively Inhibits the Growth of PI3K/PTEN Pathway–Mutant Cancers with Wild-Type KRAS and BRAF by Destabilizing Aurora Kinase B

Author

Xu, Jia, primary, Yu, Xufen, primary, Martin, Tiphaine C., primary, Bansal, Ankita, primary, Cheung, Kakit, primary, Lubin, Abigail, primary, Stratikopoulos, Elias, primary, Cahuzac, Kaitlyn M., primary, Wang, Li, primary, Xie, Ling, primary, Zhou, Royce, primary, Shen, Yudao, primary, Wu, Xuewei, primary, Yao, Shen, primary, Qiao, Ruifang, primary, Poulikakos, Poulikos I., primary, Chen, Xian, primary, Liu, Jing, primary, Jin, Jian, primary, and Parsons, Ramon, primary

Published
2023
Full Text
View/download PDF

29. Supplementary Video 3 from Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling

Author

Adamopoulos, Christos, primary, Ahmed, Tamer A., primary, Tucker, Maxwell R., primary, Ung, Peter M.U., primary, Xiao, Min, primary, Karoulia, Zoi, primary, Amabile, Angelo, primary, Wu, Xuewei, primary, Aaronson, Stuart A., primary, Ang, Celina, primary, Rebecca, Vito W., primary, Brown, Brian D., primary, Schlessinger, Avner, primary, Herlyn, Meenhard, primary, Wang, Qi, primary, Shaw, David E., primary, and Poulikakos, Poulikos I., primary

Published
2023
Full Text
View/download PDF

30. Supplementary Video 1 from Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling

Author

Adamopoulos, Christos, primary, Ahmed, Tamer A., primary, Tucker, Maxwell R., primary, Ung, Peter M.U., primary, Xiao, Min, primary, Karoulia, Zoi, primary, Amabile, Angelo, primary, Wu, Xuewei, primary, Aaronson, Stuart A., primary, Ang, Celina, primary, Rebecca, Vito W., primary, Brown, Brian D., primary, Schlessinger, Avner, primary, Herlyn, Meenhard, primary, Wang, Qi, primary, Shaw, David E., primary, and Poulikakos, Poulikos I., primary

Published
2023
Full Text
View/download PDF

32. Supplementary Figure S7 from Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies

Author

Krepler, Clemens, primary, Xiao, Min, primary, Sproesser, Katrin, primary, Brafford, Patricia A., primary, Shannan, Batool, primary, Beqiri, Marilda, primary, Liu, Qin, primary, Xu, Wei, primary, Garman, Bradley, primary, Nathanson, Katherine L., primary, Xu, Xiaowei, primary, Karakousis, Giorgos C., primary, Mills, Gordon B., primary, Lu, Yiling, primary, Ahmed, Tamer A., primary, Poulikakos, Poulikos I., primary, Caponigro, Giordano, primary, Boehm, Markus, primary, Peters, Malte, primary, Schuchter, Lynn M., primary, Weeraratna, Ashani T., primary, and Herlyn, Meenhard, primary

Published
2023
Full Text
View/download PDF

33. Supplementary Table S1 and Figure Legends from Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies

Author

Krepler, Clemens, primary, Xiao, Min, primary, Sproesser, Katrin, primary, Brafford, Patricia A., primary, Shannan, Batool, primary, Beqiri, Marilda, primary, Liu, Qin, primary, Xu, Wei, primary, Garman, Bradley, primary, Nathanson, Katherine L., primary, Xu, Xiaowei, primary, Karakousis, Giorgos C., primary, Mills, Gordon B., primary, Lu, Yiling, primary, Ahmed, Tamer A., primary, Poulikakos, Poulikos I., primary, Caponigro, Giordano, primary, Boehm, Markus, primary, Peters, Malte, primary, Schuchter, Lynn M., primary, Weeraratna, Ashani T., primary, and Herlyn, Meenhard, primary

Published
2023
Full Text
View/download PDF

34. Data from Enhanced Inhibition of ERK Signaling by a Novel Allosteric MEK Inhibitor, CH5126766, That Suppresses Feedback Reactivation of RAF Activity

Author

Ishii, Nobuya, primary, Harada, Naoki, primary, Joseph, Eric W., primary, Ohara, Kazuhiro, primary, Miura, Takaaki, primary, Sakamoto, Hiroshi, primary, Matsuda, Yutaka, primary, Tomii, Yasushi, primary, Tachibana-Kondo, Yukako, primary, Iikura, Hitoshi, primary, Aoki, Toshihiro, primary, Shimma, Nobuo, primary, Arisawa, Mikio, primary, Sowa, Yoshihiro, primary, Poulikakos, Poulikos I., primary, Rosen, Neal, primary, Aoki, Yuko, primary, and Sakai, Toshiyuki, primary

Published
2023
Full Text
View/download PDF

35. Supplementary Materials and Methods from Enhanced Inhibition of ERK Signaling by a Novel Allosteric MEK Inhibitor, CH5126766, That Suppresses Feedback Reactivation of RAF Activity

Author

Ishii, Nobuya, primary, Harada, Naoki, primary, Joseph, Eric W., primary, Ohara, Kazuhiro, primary, Miura, Takaaki, primary, Sakamoto, Hiroshi, primary, Matsuda, Yutaka, primary, Tomii, Yasushi, primary, Tachibana-Kondo, Yukako, primary, Iikura, Hitoshi, primary, Aoki, Toshihiro, primary, Shimma, Nobuo, primary, Arisawa, Mikio, primary, Sowa, Yoshihiro, primary, Poulikakos, Poulikos I., primary, Rosen, Neal, primary, Aoki, Yuko, primary, and Sakai, Toshiyuki, primary

Published
2023
Full Text
View/download PDF

36. Supplementary Figure S2 from Enhanced Inhibition of ERK Signaling by a Novel Allosteric MEK Inhibitor, CH5126766, That Suppresses Feedback Reactivation of RAF Activity

Author

Ishii, Nobuya, primary, Harada, Naoki, primary, Joseph, Eric W., primary, Ohara, Kazuhiro, primary, Miura, Takaaki, primary, Sakamoto, Hiroshi, primary, Matsuda, Yutaka, primary, Tomii, Yasushi, primary, Tachibana-Kondo, Yukako, primary, Iikura, Hitoshi, primary, Aoki, Toshihiro, primary, Shimma, Nobuo, primary, Arisawa, Mikio, primary, Sowa, Yoshihiro, primary, Poulikakos, Poulikos I., primary, Rosen, Neal, primary, Aoki, Yuko, primary, and Sakai, Toshiyuki, primary

Published
2023
Full Text
View/download PDF

37. Supplementary Table S2 from Enhanced Inhibition of ERK Signaling by a Novel Allosteric MEK Inhibitor, CH5126766, That Suppresses Feedback Reactivation of RAF Activity

Author

Ishii, Nobuya, primary, Harada, Naoki, primary, Joseph, Eric W., primary, Ohara, Kazuhiro, primary, Miura, Takaaki, primary, Sakamoto, Hiroshi, primary, Matsuda, Yutaka, primary, Tomii, Yasushi, primary, Tachibana-Kondo, Yukako, primary, Iikura, Hitoshi, primary, Aoki, Toshihiro, primary, Shimma, Nobuo, primary, Arisawa, Mikio, primary, Sowa, Yoshihiro, primary, Poulikakos, Poulikos I., primary, Rosen, Neal, primary, Aoki, Yuko, primary, and Sakai, Toshiyuki, primary

Published
2023
Full Text
View/download PDF

40. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis

Author

Chakraborty, Rikhia, Hampton, Oliver A., Shen, Xiaoyun, Simko, Stephen J., Shih, Albert, Abhyankar, Harshal, Lim, Karen Phaik Har, Covington, Kyle R., Trevino, Lisa, Dewal, Ninad, Muzny, Donna M., Doddapaneni, Harshavardhan, Hu, Jianhong, Wang, Linghua, Lupo, Philip J., Hicks, M. John, Bonilla, Diana L., Dwyer, Karen C., Berres, Marie-Luise, Poulikakos, Poulikos I., Merad, Miriam, McClain, Kenneth L., Wheeler, David A., Allen, Carl E., and Parsons, D. Williams

Published
2014
Full Text
View/download PDF

42. Abstract LB195: AKT degradation selectively inhibits the growth of PI3K/PTEN pathway mutant cancers with wild type KRAS and BRAF by destabilizing Aurora kinase B

Author

Xu, Jia, primary, Yu, Xufen, additional, Martin, Tiphaine C., additional, Bansal, Ankita, additional, Cheung, Kakit, additional, Lubin, Abigail, additional, Stratikopoulos, Elias, additional, Cahuzac, Kaitlyn M., additional, Wang, Li, additional, Xie, Ling, additional, Zhou, Royce, additional, Shen, Yudao, additional, Wu, Xuewei, additional, Yao, Shen, additional, Qiao, Ruifang, additional, Poulikakos, Poulikos I., additional, Chen, Xian, additional, Liu, Jing, additional, Jin, Jian, additional, and Parsons, Ramon, additional

Published
2022
Full Text
View/download PDF

43. Abstract LB083: BRAF dimer-selective inhibitors synergize with BRAF monomer-selective inhibitors to overcome adaptive resistance and retain therapeutic index

Author

Adamopoulos, Christos, primary, Ahmed, Tamer, additional, Ung, Peter M., additional, Xiao, Min, additional, Aaronson, Stuart, additional, Ang, Celina, additional, Rebecca, Vito, additional, Schlessinger, Avner, additional, Herlyn, Meenhard, additional, and Poulikakos, Poulikos I., additional

Published
2022
Full Text
View/download PDF

45. Additional file 1 of Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation

Author

Elnaggar, Muhammad, Agte, Sarita, Restrepo, Paula, Ram, Meghana, Melnekoff, David, Adamopoulos, Christos, Stevens, Mark M., Kappes, Katerina, Leshchenko, Violetta, Verina, Daniel, Jagannath, Sundar, Poulikakos, Poulikos I., Parekh, Samir, and Laganà, Alessandro

Abstract

Additional file 1. Laboratory measurement levels of light chain values.

Published
2022
Full Text
View/download PDF

49. Triple MAPK Inhibition Salvaged a Relapsed Post BCMA CAR-T Cell Therapy in Multiple Myeloma Patient with BRAF V600E Dominant Clone

Author

Elnaggar, Muhammad, primary, Melnekoff, David T., additional, Agte, Sarita, additional, Adamopoulos, Christos, additional, Stevens, Mark M., additional, Leshchenko, Violetta, additional, Kappes, Katerina, additional, Verina, Daniel, additional, Poulikakos, Poulikos I., additional, Jagannath, Sundar, additional, and Parekh, Samir, additional

Published
2021
Full Text
View/download PDF

50. P-090: BRAF V600E multiple myeloma patient salvaged with triple MAPK inhibition after CAR T relapse

Author

Agte, Sarita, primary, Elnaggar, Muhammad, additional, Adamopolous, Christos, additional, Melnekoff, David, additional, Adleman, Adolfo, additional, Kappes, Katerina, additional, Restrepo, Paula, additional, Oekelen, Oliver Van, additional, Leshchenko, Violetta, additional, Poulikakos, Poulikos I, additional, Lagana, Alessandro, additional, Verina, Daniel, additional, Jagannath, Sundar, additional, and Parekh, Samir, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results